I am still thinking about it all. One thing we have not been told is how much it is going to cost to do the HAL/HAP studies. Will the $4 million plus the reduced cash burn over the next three quarters (until the company thinks it reaches cash flow positive status) be enough to pay for those studies and the burn? If not there is another raise in our future. But, we also don't know anything about the potential for new ANDA's being approved during the next nine months or other deals being done that could provide cash. I am not sure yet if I am ready to average down but I am certainly closer to that point since the cash gives them some possibility of getting to cash flow breakeven without another raise.
I am pleased we were not thrown under the bus. The opposite side of that coin, however, is progress on Regbatin, PODRAS and whatever else Odidi might be working on that holds a lot of promise for shareholders is postponed again.
So, right now, we have a company which will likely only have sales and hopefully earnings from ANDA's between now and late 2019 when perhaps RExista will finally start generating revenues (Mackie says not until 2020). That is a long time to wait. A Rexista approval and partnership deal with Purdue or someone else would certainly help make the wait seem shorter but there are no guarantees on either front. The stock will not get a decent PE multiple until Rexista is a reality or PODRAS gets further down the line. Hopefully, some of the $4 million can be spent on advancing PODRAS and a partnership opportunity from that can arise faster than we now think likely.
Like I said, I am still trying to sort it all out. The stock is still dirt cheap even if all we have is ANDA's for the next 18-24 months. But I have to believe there will be more than that. I just would like more communication from the company about everything and I certainly would like to feel more confident about the number of shares the company will have outstanding in 2019.
